Vietnam Diabetes Care Devices Market Size, Share, Trends And Forecast Report 2025-2033

(MENAFN- IMARC Group) The Vietnam Diabetes Care Devices Market is on a steady, policy-supported path. In 2024, the market size reached USD 136.8 million and is projected to hit USD 160.8 million by 2033, reflecting a CAGR of 1.80% (2025–2033). Growth is underpinned by rising disease awareness, gradual insurance expansion, and the rollout of more user-friendly monitoring and insulin-delivery technologies. Key brands present include Abbott, Roche, LifeScan, and Medtronic-with Vietnam's healthcare reforms and community screening initiatives creating clearer pathways for adoption.

Request Sample For PDF Report: https://www.imarcgroup.com/vietnam-diabetes-care-devices-market/requestsample

Key Highlights

• Market size (2024): USD 136.8 million
• Forecast (2033): USD 160.8 million
• CAGR (2025–2033): 1.80%
• Momentum factors: rising diabetes prevalence, proactive awareness campaigns, improving access to care, and device innovation.

Market Trends and Drivers

• Rising Prevalence & Underdiagnosis: Vietnam faces a sharp increase in diabetes, with an estimated ~7 million people living with the condition and around half undiagnosed, intensifying demand for screening and at-home monitoring tools.
• Primary Healthcare Strengthening: WHO-supported pilots in Ho Chi Minh City bring NCD care (including diabetes) closer to communities-supporting uptake of glucometers, strips, and education on proper use.
• Tech Upgrade Cycle: Vietnam already has access to Abbott's FreeStyle Libre (flash glucose monitoring), broadening the market beyond finger-prick testing and nudging patients toward continuous insights. Globally, Roche's AI-enabled Accu-Chek SmartGuide CGM (with CE Mark in 2024) signals the next wave-predictive alerts and better nocturnal hypoglycemia risk management-features likely to shape buyer expectations in Vietnam.
• Affordability/Availability Focus: Recent multi-country device surveys note brand presence and retail channel dynamics in Vietnam's private sector, highlighting the importance of price and access for SMBG supplies.

Market Segmentation

By Devices

• Monitoring Devices
  • Self-Monitoring Blood Glucose (SMBG) Devices
  • Continuous Glucose Monitoring (CGM)
• Management Devices
  • Insulin Pumps
  • Insulin Syringes
  • Insulin Cartridges
  • Disposable Pens

By Region

• Northern Vietnam
• Central Vietnam
• Southern Vietnam
  Latest News & Developments

• Public Health Signal (July 2025): Vietnam News reports ~7 million people with diabetes and >50% undiagnosed , intensifying screening and device needs.
• Primary Care Pilot (July 2024): WHO-supported program in HCMC improves access to NCD services, a tailwind for SMBG and education-driven adherence.
• Device Access & Innovation:
  • FreeStyle Libre availability in Vietnam continues to expand CGM/flash adoption pathways.
  • Roche's AI-enabled CGM (CE Mark, 2024) showcases predictive features that could influence physician and patient preferences in Vietnam over the medium term.

Ask Analyst Report: https://www.imarcgroup.com/request?type=report&id=13447&flag=C

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales[@]imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302

MENAFN18082025004122016232ID1109939982